May 20th 2024
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Targeted drugs lengthen survival for melanoma patients
April 1st 2014Though a cure for melanoma remains elusive, continued research has borne several promising treatment approaches with more targeted drugs that can help lengthen melanoma patients' survival, buying them time until more effective treatments come to light.
Gene profiling test identifies melanoma tumors likely to metastasize
March 25th 2014In the battle against melanoma, a new test has shown that it can identify primary cutaneous melanomas that are likely to metastasize in patients who had negative sentinel lymph node biopsies (SLNB). Data were presented at the 72nd Annual Meeting of the American Academy of Dermatology.
Clinicians emphasize risk of skin cancer in patients with skin of color
March 25th 2014There is a misconception that people with skin of color are not at risk of skin cancer, and dermatologists are responsible for better educating themselves and their patients about this danger, says an expert who spoke at the 72nd Annual Meeting of the American Academy of Dermatology.
Fungal infections may mimic malignancies
March 1st 2014Common diseases can present in unusual ways, so treatment-resistant fungal infections on the skin should be biopsied, as these infections can mimic or coexist with malignancies, according to research presented at the annual meeting of the Canadian Dermatology Association.
Update: Actinic Keratoses | Guidelines aim to standardize, advance actinic keratoses treatments
March 1st 2014Dermatologists and other medical specialists around the world who treat patients with actinic keratoses (AKs or solar keratoses) will soon be able to refer to new evidence-based (S3) guidelines for management.
Resistance to BRAF inhibitors may be overcome with malaria drug
February 24th 2014Though half of melanoma patients with the BRAF mutation respond positively to treatment with BRAF inhibitors, most develop resistance to the drugs and experience disease progression. A new study suggests a drug used to treat malaria may help to block the pathway that causes this BRAF inhibitor resistance.
Rising skin cancer rate spurs drive for new therapies
February 1st 2014The commercialization of ingenol mebutate (Picato, LEO Pharma) a medication that is currently approved in the United States and many other countries for the treatment of actinic keratosis, is an example of how enthusiasm and commitment can drive innovation, a LEO Pharma general manager says.
Questionnaires measure quality-of-life impact of carcinomas
January 21st 2014In an effort to learn more about patients’ experiences with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome, researchers have developed two new questionnaires to evaluate and assess the effects of the diseases.
SCC staging update defines high-risk tumors
January 1st 2014A new tumor staging system for cutaneous squamous cell carcinoma (CSCC) has recently been put forward that, according to one recent study, improves prognostic discrimination by more precisely defining the small subset of tumors with a high risk of metastatic and death.
Initial accurate diagnosis critical for rare tumors
January 1st 2014Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) share a similar histological picture. But unlike AFX, UPS can have an aggressive clinical course, underscoring the importance of initial accurate diagnosis of these tumors, and the implementation of appropriate therapy.